Eisai's commitment to innovative solutions in disease prevention, treatment and care
for the health and well being of people worldwide is embodied in our human health
care (hhc) mission. human health care (hhc) means we give first thoughts to patients
and their families by helping to ensure access to necessary medicines.
On this site you will find information related to coding, coverage and reimbursement for select
Eisai products and information about Patient Assistance Programs which may be available
to patients in need.
Phone: 1-866-61-EISAI (1-866-61-34724)
Fax: 1-866-57-EISAI (1-866-57-34724)
Monday - Friday 8AM - 8PM ET
FRAGMIN® is a low molecular weight heparin (LMWH) indicated for:
Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions and Drug Interactions].
For more information about FRAGMIN, please see Full Product Information.
HEXALEN® (altretamine) is indicated for use as a single
agent in the palliative treatment of patients
with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based
Please see the HEXALEN® full prescribing information including Boxed WARNINGS and additional important safety information.
Targretin® capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Targretin® capsules must not be given to a pregnant woman or a woman who intends to become pregnant. If a woman becomes pregnant while taking Targretin® capsules, Tagretin must be stopped immediately and the woman given appropriate counseling.
Targretin® capsules induce major lipid abnormalities in most patients which must be monitored and treated during long term therapy. Fasting blood lipid determinations should be performed before therapy is initiated and weekly until the lipid response to Targretin® is established (usually within 2-4 weeks) and at 8 week intervals thereafter. If fasting triglycerides are elevated or become elevated during treatment, antilipemic therapy should be instituted, and if necessary, the dose of Targretin® should be reduced or suspended.
Concomitant administration of Targretin® capsules and gemfibrozil resulted in substantial increases in plasma bexarotene and is not recommended.
Acute pancreatitis has been reported. Patients with CTCL who have risk factors for pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity) should generally not be treated with Targretin® capsules.
Elevations of liver function tests (LFTs) have been observed. Baseline LFTs should be obtained, and LFTs should be carefully monitored after 1, 2 and 4 weeks of treatment initiation, and if stable, every 8 weeks thereafter during treatment. Suspension or discontinuation of Targretin® capsules should be considered if test results reach >3 times the upper limit of normal values for SGOT/AST, SGPT/ALT, or bilirubin. Targretin® capsules should only be used with great caution in patients with hepatic insufficiency.
Targretin® capsules can induce clinical hypothyroidism, causing a reversible reduction in thyroid hormone levels. Treatment with thyroid hormone supplements should be considered in these patients.
Baseline thyroid function tests should be obtained and patients monitored during treatment with Targretin® capsules.
Reversible leukopenia has been reported with treatment at certain doses of Targretin® capsules.
Targretin® capsules should be used with caution in patients with a known hypersensitivity to retinoids.
Retinoids as a class have been associated with photosensitivity. Patients should be advised to minimize exposure to sunlight and artificial ultraviolet light while receiving Targretin® capsules.
The most commonly reported adverse events in clinical trials include hyperlipemia, hypercholesterolemia, headache, asthenia, hypothyroidism, leukpenia, and diarrhea.
Please see the Targretin® Capsules full prescribing information including Boxed WARNING and additional important safety information.
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries.
CORP0130H ©2013 – Eisai Inc. All rights reserved.
This site was last modified on : January 24, 2013 at 4:30m ET